Literature DB >> 8508412

bcl-2 rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features.

J O Jacobson1, B M Wilkes, D J Kwaiatkowski, L J Medeiros, A C Aisenberg, N L Harris.   

Abstract

BACKGROUND: The frequency and clinical significance of bcl-2 rearrangement in de novo B-cell diffuse large cell lymphoma is largely unknown.
METHODS: Using Southern blot hybridization and multiple DNA probes, the status of the protooncogene bcl-2 was investigated in frozen tissue samples from 45 carefully selected cases of de novo diffuse large cell lymphoma of B-cell origin. Results were correlated with the presenting clinical and immunophenotypic features and with the subsequent clinical course.
RESULTS: Rearrangements of bcl-2 were identified in nine tumor specimens (20%). The bcl-2-positive cases more often presented as early-stage, nonmucosal associated extranodal tumors (P = 0.06) and were more often HLA-DR negative (P = 0.07). Five-year failure-free survival was poor among the bcl-2-positive cases (11% versus 48%). Overall survival was no different, however, because relapses in bcl-2-positive cases tended to be responsive to further therapy.
CONCLUSIONS: Analysis of bcl-2 rearrangements in de novo diffuse large cell lymphoma may identify a subset of patients with unusual clinical features.

Entities:  

Mesh:

Year:  1993        PMID: 8508412     DOI: 10.1002/1097-0142(19930701)72:1<231::aid-cncr2820720141>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.

Authors:  Indraneel Bhattacharyya; Hardeep K Chehal; Donald M Cohen; Samer Z Al-Quran
Journal:  Head Neck Pathol       Date:  2010-06-09

2.  Incidence of diffuse large B-cell lymphoma of germinal center B-cell origin in whole diffuse large B-cell lymphoma: tissue fluorescence in situ hybridization using t(14;18) compared with immunohistochemistry.

Authors:  Yuko Hirose; Yasufumi Masaki; Hiromi Karasawa; Kumiko Shimoyama; Toshihiro Fukushima; Hiroshi Kawabata; Noriyoshi Ogawa; Yuji Wano; Mamoru Ozaki
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

3.  Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma.

Authors:  Dana J Wallace; DeFen Shen; George F Reed; Masaru Miyanaga; Manabu Mochizuki; H Nida Sen; Samuel S Dahr; Ronald R Buggage; Robert B Nussenblatt; Chi-Chao Chan
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-07       Impact factor: 4.799

Review 4.  Pathophysiology of retinal lymphoma.

Authors:  Sarah E Coupland; Chi Chao Chan; Justine Smith
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

5.  Microarray analysis of B-cell lymphoma cell lines with the t(14;18).

Authors:  Ryan S Robetorye; Sandra D Bohling; John W Morgan; G Chris Fillmore; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

6.  De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.

Authors:  A Matolcsy; A Chadburn; D M Knowles
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

7.  Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome.

Authors:  Sarah E Coupland; Nikolaos E Bechrakis; Gerasimos Anastassiou; Andreas M H Foerster; Arnd Heiligenhaus; Uwe Pleyer; Michael Hummel; Harald Stein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-09-30       Impact factor: 3.117

8.  Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas.

Authors:  Alexandar Tzankov; Philip Went; Stephan Dirnhofer
Journal:  Biomark Insights       Date:  2007-11-11

9.  A long-term retrospective study on sporadic Burkitt lymphoma in chinese population.

Authors:  Xiaoyun Yang; Qianru Huang; An Li; Yuan Chen; Wei Xu; Jianyong Li; Yaping Wang; Yongjun Fang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.